Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...

Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations, disease ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

Chemotherapeutic agents are often used to treat cancer. They combat tumor growth, but also have a number of undesirable side ...

Panelists discuss how the inclusion of ibrutinib on the Inflation Reduction Act (IRA) negotiated drug price list could make it a more economically attractive first-line option, potentially influencing ...

Additionally, Hohl exercised stock options to acquire 3,250 shares at a price of $2.48 per share, with a total value of ...

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Gossamer Bio (GOSS – Research Report). The associated price ...

Inhibikase Therapeutics, Inc.’s IKT share price has dipped by 31.43%, which has investors questioning if this is right time ...

Researchers from the National Health Research Institutes of Taiwan described the efficacy of BPR1J481, a multitarget tyrosine kinase inhibitor in PDX-derived colorectal cancer cells, which retain the ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...